SynAct Pharma

Sweden
Lund, Skane Lan, Sweden
+45 28 44 75 67 ★

Company profile

SynAct Pharma company profile

SynAct Pharma AB develops drugs for acute deterioration in inflammatory diseases. The company's drug candidate AP1189 is intended for the treatment of arthritis including psoriatic arthritis - a form of acute joint disorder that affects approximately 30 percent of patients suffering from psoriasis. Preclinical studies show that AP1189 has a unique ability to both reduce inflammation and accelerate bleeding, which is expected to reduce joint damage that may occur after acute inflammation of the joints of the joints. AP1189 has the potential to be given in tablet form once a day. Results from a clinical phase I study are expected..... For more information, log in to dureach.com to view the full company profile.

Business identity

Contact email
[email protected]
Phone number
+45 28 44 75 67
Operating status
Active
Company type
For Profit
Employee range
00001-00010 employees
Revenue range
$1K+
Founded
2012-01-01

Headquarters

Headquarters
Lund, Skane Lan, Sweden
Postal code
223 81
Country code
SE
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Ipo
Funding rounds
3
Total equity funding
$7.8M
Last funding
Post Ipo Equity / $1.8M / 2025-07-15
Last equity funding
Post Ipo Equity / $1.8M
Investors
2
Lead investors
1
Founders
1
Articles
48
Exited on
2021-05-07

Founders and investors

Founders

Jeppe Ovli Ovlesen

Lead investors

Heights Capital Management

Investors

EISMEAHeights Capital Management

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.